• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthOpioid Crisis

DEA Whistleblower Blasts Drug Distributors, Congress Over Opioid ‘Collusion’

By
David Meyer
David Meyer
and
Geoffrey Smith
Down Arrow Button Icon
October 16, 2017, 9:29 AM ET

The U.S.’s biggest drug distributors and some of its most senior politicians colluded to fuel the country’s opioid epidemic, leading directly to thousands of unnecessary deaths.

That was the conclusion of a former Drug Enforcement Agency official whose blistering testimony was carried on last night’s edition of 60 Minutes on CBS and in the Washington Post, which also participated in the investigation.

“This is an industry that’s out of control. If they don’t follow the law in drug supply, and diversion occurs, people die. That’s just it, people die,” Joe Rannazzisi, the former DEA agent turned whistleblower, told CBS. He’s now advising lawyers suing the opioid industry.

Rannazzisi singled out the country’s three biggest drug distribution companies for criticism: Cardinal Health (CAH), McKesson (MCK) and AmerisourceBergen (ABC). Together the three account for almost 90 percent of their market, he explained.

Read: Cigna Escalates War on Opioids With OxyContin Crackdown. Is It About Public Health or Business?

Bill Whitaker said he was implying that “these big companies knew that they were pumping drugs into American communities that were killing people.”

“That’s not an implication, that’s a fact,” Rannazzisi replied. “That’s exactly what they did…This is an industry that allowed millions and millions of drugs to go into bad pharmacies and doctors’ offices that distributed them out to people who had no legitimate need for those drugs.”

McKesson didn’t respond immediately to the allegations. Cardinal issued a statement saying that: “Our people care deeply about this issue and the devastation it has caused American families and communities. We will continue to work alongside regulators, manufacturers, prescribers, pharmacists, educators, patients and others to fight opioid abuse and addiction.” (For the full statement, click here).

AmerisourceBergen CEO Steve Collis argued in a recent blog post that distributors merely execute what is demanded from pharmacies and approved by the DEA.

“We report the quantity and details of every order of opioid-based medication we ship directly to the DEA on a daily basis,” Collis wrote. “We use complex algorithms to identify and stop orders that are deemed to be suspicious. In fact, we’ve reported and stopped tens of thousands of suspicious orders since 2007, not to mention the countless other orders that pharmacies never had the opportunity to place because we declined to service them altogether.”

The Healthcare Distribution Alliance, an industry lobby group, meanwhile argued in a statement that it had been raising concerns about prescription of painkillers for years but the DEA had failed to respond.

“Our industry has continuously sought opportunities to communicate and coordinate more effectively with DEA to better understand our reporting responsibilities under the Controlled Substances Act, and to work together to mitigate the opioid epidemic,” the HDA said. “Prior to 2016, these efforts were not reciprocated — as noted by the Government Accountability Office (GAO) in a July 2015 report.”

Read: Big Pharma Is Getting Hit With a Huge Wave of Opioid Suits

A law signed by then-president Barack Obama last year made it much more difficult for the Drug Enforcement Agency (DEA) to crack down on the illegal distribution and sale of prescription painkillers such as Vicodin and oxycodone, the investigation found.

The law in question, the Ensuring Patient Access and Effective Drug Enforcement Act, was championed by Republican congressman Tom Marino and—according to the story—largely written by D. Linden Barber, a former DEA lawyer who went on to work for the drug companies. Marino is currently Donald Trump’s pick to head the Office of National Drug Control Policy.

The law was supposed to aid enforcement by improving ties with industry. However, it made a crucial change to the standard required for the DEA to freeze drug shipments that it suspected were finding their way to addicts in opioid-ravaged communities. For four decades, the DEA could freeze shipments that posed an “imminent danger,” but the law changed that to “a substantial likelihood of an immediate threat.”

Read: As America’s Opioid Crisis Spirals, Giant Drug Distributor McKesson Is Feeling the Pain

The Washington Post noted that, in a draft article written for the Marquette Law Review, DEA chief administrative law judge John Mulrooney said the law “imposed a dramatic diminution of the agency’s authority” that made it “all but logically impossible” to stop a drug company distributing its wares for non-compliance with federal law.

According to the article, the White House did not appreciate the impact of the change when Obama signed the law. However, despite the fact that the opioid epidemic has reached the level of “national emergency,” not one order has been made against a distributor or manufacturer since late 2015.

The Post said it is currently suing the Justice Department to get its hands on public records that might clarify what happened.

The DEA said Monday that it was doing everything it could to fight the opioid epidemic. “During the past seven years, we have removed approximately 900 registrations annually, preventing reckless doctors and rogue businesses from making an already troubling problem worse,” it said in a statement. CBS also reported that the Justice Department did not dispute any of the 60 Minutes story.

UPDATE: This article has been updated to include comment from AmerisourceBergen and the HDA.

About the Authors
By David Meyer
LinkedIn icon
See full bioRight Arrow Button Icon
By Geoffrey Smith
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.


Latest in Health

Man checking watch as he walks through forrest
Successchief executive officer (CEO)
CEOs reveal their New Year’s resolutions for 2026: From 8-day bike races and AI training, to finally cracking 7 hours of sleep a night
By Emma BurleighDecember 24, 2025
24 hours ago
Best protein lead image
HealthDietary Supplements
The 9 Best Protein Powders of 2025: How to Choose, According to an RD
By Christina SnyderDecember 23, 2025
2 days ago
Transparent Labs Creatine HMB as best creatine
HealthDietary Supplements
The Best Creatine Supplements of 2025: Tested and Approved
By Christina SnyderDecember 23, 2025
2 days ago
HealthDietary Supplements
The Best Hair Loss Treatments of 2025: Tested and Approved by Experts
By Christina SnyderDecember 23, 2025
2 days ago
Hims Hair loss treatment
HealthDietary Supplements
Hims Hair Loss Review 2025: Pros, Cons, and More From Hands-On Testing
By Christina SnyderDecember 22, 2025
3 days ago
David Ko stands in front of a blue and purple "Fortune" background.
Healthchief executive officer (CEO)
The CEO behind the world’s top sleep and meditation app says most leaders are operating at ‘about 20%’ without a ‘fully recharged’ battery
By Sasha RogelbergDecember 19, 2025
6 days ago

Most Popular

placeholder alt text
Retail
Trump just declared Christmas Eve a national holiday. Here’s what’s open and closed
By Dave SmithDecember 24, 2025
22 hours ago
placeholder alt text
Personal Finance
Trump turns government into giant debt collector with threat to garnish wages on millions of Americans in default on student loans
By Annie Ma and The Associated PressDecember 24, 2025
22 hours ago
placeholder alt text
Personal Finance
Financial experts warn future winner of the $1.7 billion Powerball: Don't make these common money mistakes
By Ashley LutzDecember 23, 2025
2 days ago
placeholder alt text
Economy
Obama's former top economic advisor says he feels 'a tiny bit bad' for Trump because gas prices are low, but consumer confidence is still plummeting 
By Sasha RogelbergDecember 24, 2025
15 hours ago
placeholder alt text
Law
Disgraced millennial Frank founder Charlie Javice hits JPMorgan with $74 million legal bill, including $530 in gummy bears and $347 'afternoon snack'
By Sasha RogelbergDecember 23, 2025
2 days ago
placeholder alt text
Success
Billionaire philanthropy's growing divide: Mark Zuckerberg stops funding immigration reform as MacKenzie Scott doubles down on DEI
By Ashley LutzDecember 22, 2025
3 days ago